Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

NCRI 2018 | Immunotherapeutic landscape for head and neck cancer

Quynh-Thu Le • 8 Nov 2018
NCRI 2018
Head and Neck Cancer Antibodies Checkpoint Inhibitors

Speaking from the 2018 National Cancer Research Institute (NCRI) Cancer Conference, held in Glasgow, UK, Quynh-Thu Le, MD, from Stanford University, Stanford, CA, discusses the current immunotherapeutic landscape for head and neck cancer. Prof. Le discusses the progress made in the recurrent setting, and highlights investigations now moving into the frontline. She also explains the toxicities to be aware of when using immunotherapy in this malignancy.

More from Quynh-Thu Le

3:28
Head and neck cancer challenges & cetuximab trial updates
Quynh-Thu Le • 8 Nov 2018

Related Videos

1:03
Challenges in implementing liquid biopsies for head and neck cancer
Mouadh Barbirou • 7 Apr 2024
2:43
Molecular profiling of tumor biomarkers in head and neck cancer
Mouadh Barbirou • 7 Apr 2024
1:40
The future of squamous cell carcinoma research at ESMO Asia 2023
Brian Henick • 6 Dec 2023
0:54
The role of immunotherapy in PD-L1 low advanced squamous cell carcinoma
Brian Henick • 6 Dec 2023
The content of VJOncology is intended for healthcare professionals